Subscribe
The immunotherapy pembrolizumab (Keytruda) demonstrated on overall response rate (ORR) of 12% in patients with ER-positive, HER2-negative advanced breast cancer in the phase 1b KEYNOTE-028 trial, marking the second early-stage trial to show antitumor activity with this agent in breast cancer.
Patient-Reported Symptoms Can Inform Advice on Tamoxifen Versus Anastrozole
Early Signals of Response With PD-L1 Inhibitor Avelumab in Metastatic Breast Cancer
Denosumab Is Not Just for Bone Health—Therapy Improves Survival, Too
FDA Clears First Cooling Cap to Save Hair During Breast Cancer Chemo
November 5, 2026
1 Session is Available!
Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO
Benjamin Scheier, MD; Syma Iqbal, MD